48.89
price up icon2.15%   1.03
after-market Handel nachbörslich: 48.89
loading
Schlusskurs vom Vortag:
$47.86
Offen:
$48.12
24-Stunden-Volumen:
244.06K
Relative Volume:
0.47
Marktkapitalisierung:
$2.92B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-145.21M
KGV:
-21.26
EPS:
-2.3
Netto-Cashflow:
$-140.12M
1W Leistung:
+3.38%
1M Leistung:
+0.70%
6M Leistung:
-8.53%
1J Leistung:
+15.85%
1-Tages-Spanne:
Value
$47.87
$49.29
1-Wochen-Bereich:
Value
$46.24
$49.29
52-Wochen-Spanne:
Value
$31.42
$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Firmenname
Moonlake Immunotherapeutics
Name
Telefon
41 41 510 8022
Name
Adresse
DORFSTRASSE 29, ZUG
Name
Mitarbeiter
100
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
MLTX's Discussions on Twitter

Vergleichen Sie MLTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
48.89 2.92B 0 -145.21M -140.12M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-19 Hochstufung Wolfe Research Peer Perform → Outperform
2025-03-18 Eingeleitet RBC Capital Mkts Outperform
2025-01-17 Hochstufung Goldman Neutral → Buy
2024-11-05 Fortgesetzt Wedbush Outperform
2024-08-26 Herabstufung Wolfe Research Outperform → Peer Perform
2024-06-25 Eingeleitet Oppenheimer Outperform
2024-04-02 Eingeleitet Goldman Neutral
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-12-08 Eingeleitet Citigroup Buy
2023-11-02 Eingeleitet Stifel Buy
2023-09-14 Herabstufung Bryan Garnier Buy → Neutral
2023-08-31 Eingeleitet Needham Buy
2023-06-15 Eingeleitet Barclays Equal Weight
2023-05-01 Eingeleitet Guggenheim Buy
2023-03-22 Eingeleitet Wedbush Outperform
2023-03-09 Eingeleitet BTIG Research Buy
2023-02-14 Eingeleitet Cantor Fitzgerald Overweight
2023-02-02 Eingeleitet Bryan Garnier Buy
2022-11-11 Eingeleitet Jefferies Buy
2022-08-25 Eingeleitet SVB Leerink Outperform
2022-07-21 Eingeleitet H.C. Wainwright Buy
2022-07-07 Eingeleitet Cowen Outperform
Alle ansehen

Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten

pulisher
Jun 18, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com

Jun 18, 2025
pulisher
Jun 16, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Developments - geneonline.com

Jun 16, 2025
pulisher
Jun 15, 2025

Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 15, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Developments - geneonline.com

Jun 15, 2025
pulisher
Jun 13, 2025

MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

IIH interview: Matthias Bodenstedt discusses MoonLake’s capital raising journey, the appeal of SLK and plans for the future - Investors in Healthcare

Jun 13, 2025
pulisher
Jun 13, 2025

MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating - TipRanks

Jun 13, 2025
pulisher
Jun 12, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Focus on Inflammatory Disease Treatments - geneonline.com

Jun 12, 2025
pulisher
Jun 10, 2025

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Focus - geneonline.com

Jun 10, 2025
pulisher
Jun 09, 2025

MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks

Jun 09, 2025
pulisher
Jun 08, 2025

StockWatch: Report of $3B+ Merck Buyout Offer Propels MoonLake Stock Surge - Genetic Engineering and Biotechnology News

Jun 08, 2025
pulisher
Jun 07, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Strategic Uncertainty - geneonline.com

Jun 07, 2025
pulisher
Jun 07, 2025

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

MoonLake Immunotherapeutics Elects Directors at AGM - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Merck held talks to buy biotech MoonLake for over $3 billion - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

These Stocks Moved the Most Today: Nvidia, Tesla, Dollar General, Credo, Ferguson, Moonlake, and More - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Industry Speculation - geneonline.com

Jun 06, 2025
pulisher
Jun 05, 2025

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

MoonLake Immunotherapeutics Reportedly Considering Sale Amid Competitive Pharmaceutical Market Challenges - geneonline.com

Jun 05, 2025
pulisher
Jun 05, 2025

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help - statnews.com

Jun 05, 2025
pulisher
Jun 04, 2025

Merck's Bold Proposal Sends MoonLake's Shares Climbing - Finimize

Jun 04, 2025
pulisher
Jun 04, 2025

Merck made $3B+ offer for MoonLake earlier this yearreport - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Two Biotechs That Could Get an M&A Boost - TheStreet Pro

Jun 04, 2025
pulisher
Jun 04, 2025

Merck & Co., Inc. (MRK) Held Talks Over $3 Billion Acquisition of Swiss Biotech Firm MoonLake - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Merck in Talks to Acquire MoonLake Immunotherapeutics for $3 Billion - geneonline.com

Jun 04, 2025
pulisher
Jun 04, 2025

MSD rumoured to be eyeing $3bn+ MoonLake takeover - pharmaphorum

Jun 04, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics (MLTX) Surges 25% on Merck Acquisiti - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid - Investor's Business Daily

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX) - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Shifts - geneonline.com

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics Breaks Above 200-Day Moving AverageBullish for MLTX - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake's (MLTX) 'Outperform' Rating Reiterated by RBC Capital - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake takeover thesis reemerges after FT report, says Citi - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Shares Jump On Potential Merck Acquisition Offer - Finimize

Jun 03, 2025
pulisher
Jun 03, 2025

MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

RBC Capital maintains outperform rating on Moonlake stock By Investing.com - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

RBC Capital maintains outperform rating on Moonlake stock - Investing.com

Jun 03, 2025

Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Moonlake Immunotherapeutics-Aktie (MLTX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
BVF PARTNERS L P/IL
Director
Oct 04 '24
Sale
50.00
2,000,000
100,003,200
1,287,768
Sturge Simon
Director
Oct 04 '24
Sale
53.72
171,000
9,186,120
171,980
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Kapitalisierung:     |  Volumen (24h):